| payload |
{"created_at":"2026-04-13T14:54:53.963 {"created_at":"2026-04-13T14:54:53.963749+00:00","signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","url":"https://www.nasdaq.com/articles/revolution-medicines-stock-rises-39-over-positive-topline-data-daraxonrasib-study","value":{"fp":"f5033b4a547b887a","kind":"unusual_volume","published_at":"2026-04-13T13:46:48+00:00","source":"Nasdaq Markets","summary":"(RTTNews) - Shares of Revolution Medicines, Inc. (RVMD) are climbing about 39 percent on Monday morning trading after the company announced positive topline data from the Phase 3 RASolute trial for Daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma.","tickers":["RVMD"],"title":"Revolution Medicines Stock Rises 39% Over Positive Topline Data From Daraxonrasib Study","url":"https://www.nasdaq.com/articles/revolution-medicines-stock-rises-39-over-positive-topline-data-daraxonrasib-study"}}... |